Why This Study Matters
Consolidation durvalumab after concurrent chemoradiotherapy has been a standard-of-care option for unresectable stage III non-small-cell lung cancer (NSCLC) since the original PACIFIC trial. Regional, locally advanced NSCLC carries a five-year relative survival rate of roughly 40%, a reminder of how much rides on maximizing the benefit of immunotherapy in this setting. This post-hoc analysis asks a pointed question: do common concomitant medications that alter the gut microbiome — proton pump inhibitors (PPIs) and antibiotics — quietly erode that benefit?
Study Design
| Element | Detail |
|---|---|
| Design | Post-hoc analysis of a randomized, double-blind, placebo-controlled phase 3 trial (PACIFIC), based on the trial's final 5-year data cutoff |
| Randomization | 2:1, durvalumab vs. placebo, stratified by age, sex, and smoking history |
| Durvalumab dosing | 10 mg/kg IV every 2 weeks for up to 12 months |
| Original enrollment | 713 patients (May 2014-April 2016); 476 durvalumab / 237 placebo |
| Post-hoc analysis population | 660 patients (449 durvalumab, 211 placebo) |
| Co-primary endpoints (this analysis) | Progression-free survival (PFS) and overall survival (OS), assessed by baseline PPI/antibiotic exposure |
| Median follow-up | 62.4 months (IQR 61.9-63.2) |
Patient Population
The post-hoc population (n=660) was 30.8% female (203 patients) and 68.6% male (453 patients). Race was reported as White in 64.2% (424), Asian in 23.1% (153), Black or African American in 0.7% (5), and unknown in 11.8% (78). Eligible patients had unresectable stage III squamous or non-squamous NSCLC, WHO performance status 0-1, and no disease progression after two or more cycles of concurrent chemoradiotherapy.
Primary Endpoint Results
Among patients receiving durvalumab, baseline exposure to a proton pump inhibitor was associated with substantially shorter PFS and OS compared with no exposure:
| Outcome | PPI Exposed | PPI Unexposed | HR (95% CI) | p-value |
|---|---|---|---|---|
| PFS | 9.4 mo (7.6-13.7) | 17.2 mo (15.4-23.2) | 1.57 (1.28-1.93) | <0.0001 |
| OS | 33.0 mo (21.9-46.7) | 57.9 mo (48.7-NC) | 1.66 (1.30-2.13) | <0.0001 |
A similar, though smaller, association was seen with baseline antibiotic exposure in the durvalumab arm:
| Outcome | Antibiotic Exposed | Antibiotic Unexposed | HR (95% CI) | p-value |
|---|---|---|---|---|
| PFS | 9.2 mo (4.9-18.1) | 15.6 mo (13.6-17.6) | 1.50 (1.08-2.10) | 0.016 |
| OS | 37.7 mo (18.8-NC; 28 events) | 49.2 mo (39.7-57.3) | 1.33 (0.90-1.97) | 0.16 (not significant) |
Treatment-by-PPI interaction terms were statistically significant for both PFS (p=0.023) and OS (p<0.0001). The treatment-by-antibiotic interaction was not significant, though the abstract did not report an exact interaction p-value.
Subgroup Analyses
| Subgroup Comparison | Arm | PFS HR (95% CI, p) | OS HR (95% CI, p) |
|---|---|---|---|
| PPI exposed vs. unexposed | Durvalumab | 1.57 (1.28-1.93, p<0.0001) | 1.66 (1.30-2.13, p<0.0001) |
| Antibiotic exposed vs. unexposed | Durvalumab | 1.50 (1.08-2.10, p=0.016) | 1.33 (0.90-1.97, p=0.16) |
| PPI exposed vs. unexposed | Placebo | Not specified in source | Not specified in source |
| Antibiotic exposed vs. unexposed | Placebo | Not specified in source | Not specified in source |
The abstract describes the placebo-arm comparisons only qualitatively — "no significant change in overall survival and progression-free survival" — without reporting exact hazard ratios, confidence intervals, or p-values for the placebo subgroups, which are therefore marked as not specified rather than estimated.
Safety Profile
Not specified in source. This post-hoc analysis focused on the association between baseline PPI/antibiotic exposure and efficacy outcomes (PFS/OS); it did not report a new adverse-event comparison by exposure subgroup. Overall PACIFIC trial safety data were established in the original 2017 primary publication, which falls outside the scope of this post-hoc abstract.
The detrimental association between concomitant PPI or antibiotic use and clinical outcomes appeared to be context-dependent.
— Dr. Leonardo Brunetti, lead author
Interpretation and Broader Context
The study authors were explicit that a retrospective, post-hoc association within a randomized trial is not proof of causality: prescription rationale, timing, duration, and adherence data were unavailable for this analysis. Corresponding author Alessio Cortellini, MD, PhD (Imperial College London), and colleagues frame the findings as motivation for "careful medication stewardship" — avoiding unnecessary PPI or antibiotic prescriptions that could potentially interfere with anticancer treatment efficacy during immunotherapy.
Because the association was seen in the durvalumab arm but not the placebo arm, the authors suggest these medications may exert broader pleiotropic effects at the metabolic, immune, and pharmacogenomic level that specifically blunt checkpoint inhibitor activity, rather than simply reflecting a sicker patient population.
Future Directions
The authors describe ongoing interest in understanding how host-related factors — including pharmacologic exposures that alter the gut microbiome — shape outcomes with immune-checkpoint inhibitors, pointing toward prospective evaluation of medication stewardship strategies as a next step.
In a post-hoc analysis of the PACIFIC trial, baseline exposure to a PPI or antibiotic was linked to significantly shorter progression-free and overall survival in patients treated with durvalumab (PPI: PFS HR 1.57, OS HR 1.66; antibiotics: PFS HR 1.50), but not in patients who received placebo, and the treatment-by-PPI interaction was statistically significant for both endpoints. The retrospective, post-hoc nature of the analysis and the absence of exposure timing or adherence data mean this cannot establish causality, but it strengthens the case for careful stewardship of PPIs and antibiotics around consolidation immunotherapy in locally advanced NSCLC.